C07D 453/00
Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems
Official title: Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
C07D453/00 (Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems) appears on 1,525 US grants and 1,318 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,525
- Published applications
- 1,318
- Assignees
- 612
- Inventors
- 4,058
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 12 | 0 |
| 1977 | 12 | 0 |
| 1978 | 20 | 0 |
| 1979 | 6 | 0 |
| 1980 | 7 | 0 |
| 1981 | 4 | 0 |
| 1982 | 7 | 0 |
| 1983 | 6 | 0 |
| 1984 | 7 | 0 |
| 1985 | 8 | 0 |
| 1986 | 11 | 0 |
| 1987 | 11 | 0 |
| 1988 | 7 | 0 |
| 1989 | 19 | 0 |
| 1990 | 29 | 0 |
| 1991 | 17 | 0 |
| 1992 | 26 | 0 |
| 1993 | 48 | 0 |
| 1994 | 30 | 0 |
| 1995 | 24 | 0 |
| 1996 | 49 | 0 |
| 1997 | 43 | 0 |
| 1998 | 51 | 0 |
| 1999 | 45 | 0 |
| 2000 | 31 | 0 |
| 2001 | 33 | 2 |
| 2002 | 29 | 25 |
| 2003 | 22 | 47 |
| 2004 | 23 | 70 |
| 2005 | 29 | 86 |
| 2006 | 36 | 55 |
| 2007 | 40 | 73 |
| 2008 | 49 | 61 |
| 2009 | 46 | 67 |
| 2010 | 43 | 70 |
| 2011 | 41 | 72 |
| 2012 | 60 | 52 |
| 2013 | 63 | 64 |
| 2014 | 66 | 83 |
| 2015 | 70 | 67 |
| 2016 | 63 | 56 |
| 2017 | 61 | 53 |
| 2018 | 42 | 52 |
| 2019 | 43 | 32 |
| 2020 | 34 | 39 |
| 2021 | 20 | 30 |
| 2022 | 26 | 34 |
| 2023 | 12 | 45 |
| 2024 | 11 | 28 |
| 2025 | 19 | 20 |
| 2026 | 14 | 35 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions and methods for parasite control6 Oct 2026US 12,751,453 B2Philip Morris Products S. A.
- Ferroptosis inhibitors—diarylamine para-acetamides25 Aug 2026US 12,715,855 B2Sironax Ltd.
- Salt forms of sabcomeline18 Aug 2026US 12,709,611 B2Syremis Therapeutics, Ltd.
- Compounds having inhibitory activity against glucosylceramide synthase or pharmaceutically acceptable salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same7 Jul 2026US 12,673,944 B2The Green Cross Corporation
- Optically active bridged piperidine derivative23 Jun 2026US 12,662,494 B2Sumitomo Pharma Co., Ltd.
- Organic Photoredox Catalysts, Compositions, and Conversion Processes24 Sep 2026US 2026/0284647 A1Colorado State University Research Foundation
- Ionizable lipids for nucleic acid delivery17 Sep 2026US 2026/0273066 A1Global Life Sciences Solutions Canada ULC
- Bulky and small-steric-hindrance ligand and use thereof17 Sep 2026US 2026/0273518 A1Dg Hc Optical Co., Ltd
- 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk510 Sep 2026US 2026/0265224 A1Agomab Spain, S.L.U.
- Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof27 Aug 2026US 2026/0250265 A1Crinetics Pharmaceuticals, Inc.
Most cited
By later US patents
- N[.omega.,(.omega.-1)-dialkyloxy]- and N-[.omega.,(.omega.-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor740US 4,897,355 ASyntex (U.S.A.) Inc. · 1990
- N-(.omega.,(.omega.-1)-dialkyloxy)- and N-(.omega.,(.omega.-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor306US 4,946,787 ASyntex (U.S.A.) Inc. · 1990
- N-.omega.,(.omega.-1)-dialkyloxy)- and N-(.omega.,(.omega.-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor234US 5,049,386 ASyntex (U.S.A.) Inc. · 1991
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases232US 6,180,632 B2Aventis Pharmaceuticals Products Inc. · 2001
- Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases219US 6,482,834 B2Aventis Pharmaceuticals Inc. · 2002